A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment of epithelial ovarian cancer, the most lethal form of gynaecological cancer. This important immunoassay, which will run on Abbott's Architect systems, is the first automated HE4 test available anywhere in the world.

Research has shown that this novel diagnostic marker, combined with other tests such as the CA125 assay, can aid in measuring the risk of epithelial ovarian cancer in pre- and post-menopausal women who have a pelvic mass.

According to the International Agency for Research on Cancer, the five-year survival rate of ovarian cancer patients is 46 per cent. However, when the disease is diagnosed earlier, the survival rate increases to 94 per cent.

"The ability of this test to help physicians predict whether a pelvic mass is benign or malignant is an important development for both patients and physicians," said Michael Warmuth, senior vice president, diagnostics, Abbott. "Abbott's Architect HE4 test will aid physicians in determining the most appropriate treatment for their patients."

Abbott partnered with Fujirebio Diagnostics, Inc. in the development of the assay. The test is now available in several European countries, as well as in some countries in Asia Pacific and Latin America. The Architect HE4 Assay was recently submitted to the FDA for 510(k) clearance.

Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics.